Oxidative mechanisms contributing to the developmental neurotoxicity of nicotine and chlorpyrifos.

Published

Journal Article

Nicotine and chlorpyrifos are developmental neurotoxicants that, despite their differences in structure and mechanism of action, share many aspects for damage to the developing brain. Both are thought to generate oxidative radicals; in the current study, we evaluated their ability to produce lipid peroxidation in two in vitro models of neural cell development (PC12 and SH-SY5Y cells) and for nicotine, with treatment of adolescent rats in vivo. Nicotine and chlorpyrifos, in concentrations relevant to human exposures, elicited an increase in thiobarbituric-acid-reactive species (TBARS) in undifferentiated cells, an effect that was prevented by addition of the antioxidant, Vitamin E. Initiating differentiation with nerve growth factor, which enhances nicotinic acetylcholine receptor expression, increased the TBARS response to nicotine but not chlorpyrifos, suggesting that the two agents act by different originating mechanisms to converge on the endpoint of oxidative damage. Furthermore, nicotine protected the cells from oxidative damage evoked by chlorpyrifos and similarly blocked the antimitotic effect of chlorpyrifos. Treatment of adolescent rats with nicotine elicited increases in TBARS in multiple brain regions when given in doses that simulate plasma nicotine concentrations found in smokers or at one-tenth the dose. Our results indicate that nicotine and chlorpyrifos elicit oxidative damage to developing neural cells both in vitro and in vivo, a mechanism that explains some of the neurodevelopmental endpoints that are common to the two agents. The balance between neuroprotectant and neurotoxicant actions of nicotine may be particularly important in situations where exposure to tobacco smoke is combined with other prooxidant insults.

Full Text

Duke Authors

Cited Authors

  • Qiao, D; Seidler, FJ; Slotkin, TA

Published Date

  • August 2005

Published In

Volume / Issue

  • 206 / 1

Start / End Page

  • 17 - 26

PubMed ID

  • 15963341

Pubmed Central ID

  • 15963341

Electronic International Standard Serial Number (EISSN)

  • 1096-0333

International Standard Serial Number (ISSN)

  • 0041-008X

Digital Object Identifier (DOI)

  • 10.1016/j.taap.2004.11.003

Language

  • eng